Development of new immunotherapy for intractable gastrointestinal cancer

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K10034
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: General surgery
• Research Institution: Nara Medical University
• Principal Investigator: Sho Masayuki 奈良県立医科大学, 医学部, 教授 (50364063)
• Research Collaborator: NISHIWADA Satoshi ; KINOSHITA Shoichi
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 膵癌 / 消化器癌 / 腫瘍免疫

Outline of Final Research Achievements

In this study, we have evaluated HVEM expression in hepatocellular carcinoma and colorectal cancer. As a result, tumor HVEM expression had a significant prognostic value. Furthermore, HVEM expression was inversely correlated with tumor-infiltrating T cells, suggesting its important role in tumor immunity.
In addition, we have evaluated CD155 and Nectin family in human pancreatic cancer. We found such molecules had significant prognostic value and played an important role in pancreatic cancer. Therefore, targeting T cell negative pathways including HVEM, CD155, and Nectin family may hold significant promise for future clinical application in cancer immunotherapy.

Free Research Field

消化器外科，一般外科